Immunex Corporation and Wyeth-Ayerst Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) has approved Enbrel for the treatment of moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) in patients with inadequate response to one or more disease modifying medicines. JRA affects children before the age of sixteen and can cause deformity, joint pain, stunted growth and increased mortality.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.